(1) Background: The COVID-19 pandemic has resulted in the exacerbation of various chronic diseases. Due to the potential impact of SARS-CoV-2 on mast cells, we aimed to analyze the relevance of COVID-19 disease on chronic spontaneous urticaria (CSU) clinical presentation and biological profile. (2) Methods: This study is a retrospective case series of patients with CSU diagnosed and treated in the Allergy Department of the Professor Doctor Octavian Fodor RIGH, (Cluj-Napoca, Romania). Patients were assessed for disease activity and level of control with the weekly urticaria activity score and the visual analogue scale. Results were correlated with COVID-19 severity and with nonspecific markers of inflammation during and after the SARS-CoV-2 infection. (3) Results: SARS-CoV-2 impacted a significant proportion (33%) of the CSU patients, of which 71% developed a moderate-severe form of COVID-19. Most of the patients (68%) had moderate-severe forms of CSU and 65% took AH1 treatment (one dose, two-fold dose or four-fold dose). The rest of them (35%) received the second-line treatment (40.3% Omalizumab, 53% Prednisolone and 4.8% Cyclosporine). In Omalizumab treated group of UCS patients we observed that COVID-19 disease was not severe. We established a positive correlation between the severity of the infection and that of the CSU clinical presentation, with most bothersome symptoms of urticaria being experienced by moderate to severe COVID-19 CSU patients (47%). Inflammatory markers were positively correlated ( p = 0.01) with a more severe clinical profile of CSU, in accordance with our hypothesis that the level of inflammation triggered by COVID-19 disease has a role in CSU exacerbation. The non-specific inflammatory markers, such as CRP, were positively associated with the UAS7 score (R2 = 0.363; p = 0.001). An increased rate of exacerbation of CSU was observed in moderate-severe COVID-19 infection. (4) Conclusions: COVID-19 disease can result in the exacerbation of chronic spontaneous urticaria, more likely in moderate to severe forms of infection.
【저자키워드】 COVID-19, SARS-COV-2 infection, Mast cells, chronic spontaneous urticaria, 【초록키워드】 Treatment, SARS-CoV-2, Inflammation, severe COVID-19, COVID-19 pandemic, severity, Infection, inflammatory markers, CRP, Symptom, COVID-19 disease, COVID-19 infection, Patient, Romania, moderate, patients, non-specific, marker, Disease activity, retrospective, Hypothesis, dose, omalizumab, cyclosporine, Chronic diseases, Visual Analogue Scale, positive correlation, doctor, Professor, Department, MOST, Result, proportion, the patient, diagnosed, form, case sery, treated, correlated, triggered, impacted, AH1, biological profile, moderate-severe, nonspecific, positively correlated, the SARS-CoV-2, were assessed, with COVID-19, 【제목키워드】 chronic, urticaria, leading, Spontaneous,